Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy
Authors
Keywords
-
Journal
GENE THERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-01
DOI
10.1038/s41434-020-0156-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model
- (2019) Lucía Echevarría et al. Nucleic Acid Therapeutics
- Exons 45-55 skipping using mutation-tailored cocktails of antisense morpholinos in the DMD gene
- (2019) Yusuke Echigoya et al. MOLECULAR THERAPY
- Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy
- (2018) Alison M. Blain et al. PLoS One
- Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy
- (2018) Hirofumi Komaki et al. Science Translational Medicine
- NS-065/NCNP-01: an Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy
- (2018) Naoki Watanabe et al. Molecular Therapy-Nucleic Acids
- Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study
- (2018) Niels Hilhorst et al. EUROPEAN JOURNAL OF PEDIATRICS
- Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy
- (2017) Yusuke Echigoya et al. MOLECULAR THERAPY
- Comprehensive analysis for genetic diagnosis of Dystrophinopathies in Japan
- (2017) Mariko Okubo et al. Orphanet Journal of Rare Diseases
- Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy
- (2017) Yusuke Echigoya et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Eteplirsen in the treatment of Duchenne muscular dystrophy
- (2017) Kenji Rowel Lim et al. Drug Design Development and Therapy
- Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
- (2016) Jerry R. Mendell et al. ANNALS OF NEUROLOGY
- Eteplirsen: First Global Approval
- (2016) Yahiya Y. Syed DRUGS
- Approving a Problematic Muscular Dystrophy Drug
- (2016) Aaron S. Kesselheim et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antisense Oligonucleotide-based Splice Correction for USH2A-associated Retinal Degeneration Caused by a Frequent Deep-intronic Mutation
- (2016) Radulfus WN Slijkerman et al. Molecular Therapy-Nucleic Acids
- Exon skipping therapy for Duchenne muscular dystrophy
- (2015) Ryszard Kole et al. ADVANCED DRUG DELIVERY REVIEWS
- Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?
- (2015) Ashley Guncay et al. Future Medicinal Chemistry
- Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers
- (2015) Aurélie Goyenvalle et al. NATURE MEDICINE
- Long-Term Efficacy of Systemic Multiexon Skipping Targeting Dystrophin Exons 45–55 With a Cocktail of Vivo-Morpholinos in Mdx52 Mice
- (2015) Yusuke Echigoya et al. Molecular Therapy-Nucleic Acids
- In Silico Screening Based on Predictive Algorithms as a Design Tool for Exon Skipping Oligonucleotides in Duchenne Muscular Dystrophy
- (2015) Yusuke Echigoya et al. PLoS One
- DMD Mutations in 576 Dystrophinopathy Families: A Step Forward in Genotype-Phenotype Correlations
- (2015) Jonas Juan-Mateu et al. PLoS One
- Cell-Penetrating Peptides: Design, Synthesis, and Applications
- (2014) Dana Maria Copolovici et al. ACS Nano
- Design and evaluation of locked nucleic acid-based splice-switching oligonucleotidesin vitro
- (2014) Takenori Shimo et al. NUCLEIC ACIDS RESEARCH
- Exon-Skipping Antisense Oligonucleotides to Correct Missplicing in Neurogenetic Diseases
- (2014) Kavitha Siva et al. Nucleic Acid Therapeutics
- Newborn bloodspot screening for Duchenne Muscular Dystrophy: 21 years experience in Wales (UK)
- (2013) Stuart J Moat et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Long-Term Rescue of Dystrophin Expression and Improvement in Muscle Pathology and Function in Dystrophic mdx Mice by Peptide-Conjugated Morpholino
- (2012) Bo Wu et al. AMERICAN JOURNAL OF PATHOLOGY
- Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?
- (2012) Toshifumi Yokota et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Antisense-based therapy for the treatment of spinal muscular atrophy
- (2012) Frank Rigo et al. JOURNAL OF CELL BIOLOGY
- Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery
- (2012) Y. Aoki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mammalian Models of Duchenne Muscular Dystrophy: Pathological Characteristics and Therapeutic Applications
- (2011) Akinori Nakamura et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
- (2011) Sebahattin Cirak et al. LANCET
- Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders
- (2011) Kamel Mamchaoui et al. Skeletal Muscle
- RNA-targeted splice-correction therapy for neuromuscular disease
- (2010) M. J. A. Wood et al. BRAIN
- Therapeutic exon skipping for dysferlinopathies?
- (2010) Annemieke Aartsma-Rus et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model
- (2010) Hans Heemskerk et al. MOLECULAR THERAPY
- In-frame Dystrophin Following Exon 51-Skipping Improves Muscle Pathology and Function in the Exon 52–Deficient mdx Mouse
- (2010) Yoshitsugu Aoki et al. MOLECULAR THERAPY
- Antisense-induced Myostatin Exon Skipping Leads to Muscle Hypertrophy in Mice Following Octa guanidine Morpholino Oligomer Treatment
- (2010) Jagjeet K Kang et al. MOLECULAR THERAPY
- Efficacy of systemic morpholino exon-skipping in duchenne dystrophy dogs
- (2009) Toshifumi Yokota et al. ANNALS OF NEUROLOGY
- A Renaissance for Antisense Oligonucleotide Drugs in Neurology
- (2009) Toshifumi Yokota et al. ARCHIVES OF NEUROLOGY
- Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort
- (2009) Kevin M. Flanigan et al. HUMAN MUTATION
- Octa-guanidine Morpholino Restores Dystrophin Expression in Cardiac and Skeletal Muscles and Ameliorates Pathology in Dystrophic mdx Mice
- (2009) Bo Wu et al. MOLECULAR THERAPY
- Design of Phosphorodiamidate Morpholino Oligomers (PMOs) for the Induction of Exon Skipping of the Human DMD Gene
- (2009) Linda J Popplewell et al. MOLECULAR THERAPY
- Exon-skipping therapy for Duchenne muscular dystrophy
- (2009) Akinori Nakamura et al. NEUROPATHOLOGY
- Design and Synthesis of Dendritic Molecular Transporter that Achieves Efficientin VivoDelivery of Morpholino Antisense Oligo
- (2008) Yong-Fu Li et al. BIOCONJUGATE CHEMISTRY
- Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating Mechanisms
- (2008) Annemieke Aartsma-Rus et al. MOLECULAR THERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now